Option Care Health Reports Financial Results for Fourth Quarter and Full Year 2023

In this article:
Option Care Health, Inc.Option Care Health, Inc.
Option Care Health, Inc.

BANNOCKBURN, Ill., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the fourth quarter and full year ended December 31, 2023.

Fourth Quarter 2023 Financial Highlights

  • Net revenue of $1,124.4 million, up 9.5% compared to $1,027.2 million in the fourth quarter of 2022

  • Gross profit of $247.1 million, or 22.0% of revenue, up 6.9% compared to $231.1 million, or 22.5% of revenue, in the fourth quarter of 2022

  • Net income of $57.2 million, or $0.32 earnings per share, inclusive of the impact from non-operating income, compared to net income of $47.5 million, or $0.26 earnings per share in the fourth quarter of 2022

  • Adjusted EBITDA of $111.6 million, up 18.4% compared to $94.3 million in the fourth quarter of 2022

  • Cash flow from operations of $51.0 million, and cash balances of $343.8 million at the end of the fourth quarter

  • The Company announced that it fulfilled $250 million in share repurchases and the Board of Directors authorized an additional $250 million share repurchase authorization

Full Year 2023 Financial Highlights

  • Net revenue of $4,302.3 million, up 9.1% compared to $3,944.7 million in full year 2022

  • Gross profit of $981.2 million, or 22.8% of revenue, up 13.2% compared to $866.9 million, or 22.0% of revenue, in full year 2022

  • Net income of $267.1 million, or $1.48 diluted earnings per share, compared to net income of $150.6 million, or $0.83 earnings per share, in full year 2022

  • Adjusted EBITDA of $425.2 million, up 24.0% compared to $342.9 million in full year 2022

  • Cash flow from operations of $371.3 million, up 38.8% compared to $267.5 million in full year 2022

John C. Rademacher, Chief Executive Officer, commented, “The Option Care Health team delivered strong financial results in the fourth quarter and full year of 2023 and continued to execute on our commitment to clinical excellence by providing extraordinary patient care through our resilient national platform. The patient is at the center of everything we do, and I am excited to build on this momentum in 2024 to further our mission to provide innovative services that improve outcomes, reduce costs, and deliver hope for patients and families.”

Full Year 2024 Financial Guidance

For the full year 2024, Option Care Health expects to deliver the following financial results:

  • Net revenue of $4.6 billion to $4.8 billion

  • Adjusted EBITDA of $425 million to $450 million

  • Cash flow from operations of at least $300 million

Additionally, the Company anticipates an effective tax rate of 26% - 28% and net interest expense of approximately $55 million to $60 million.

Conference Call

Option Care Health will host a conference call to discuss its financial results later today at 8:30 a.m. EST. The conference call can be accessed via a live audio webcast that will be available online at investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members, including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at OptionCareHealth.com.

Investor Contacts

Mike Shapiro

Bob East, Asher Dewhurst, Jordan Kohnstam

Chief Financial Officer

Westwicke

T: (312) 940-2538

T: (413) 213-0500

mike.shapiro@optioncare.com

optioncarehealth@westwicke.com

 

 

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: changes in laws and regulations applicable to our business model; changes in market conditions and receptivity to our services and offerings; pending and future litigation; potential liability for claims not covered by insurance; and loss of relationships with managed care organizations and other non-governmental third party payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our periodic reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, loss on extinguishment of debt, and restructuring, acquisition, integration and other. As part of restructuring, acquisition, integration and other, the Company may incur significant charges such as the write down of certain long‑lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. We have not reconciled Adjusted EBITDA guidance to net income as management believes creation of this reconciliation would not be practicable due to the uncertainty regarding, and potential variability of, material reconciling items. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see below.


Schedule 1

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)

 


 

December 31,

 

 

2023

 

 

2022

ASSETS

 

 

 

CURRENT ASSETS:

 

 

 

Cash and cash equivalents

$

343,849

 

$

294,186

Accounts receivable, net

 

377,658

 

 

377,542

Inventories

 

274,004

 

 

224,281

Prepaid expenses and other current assets

 

98,744

 

 

98,330

Total current assets

 

1,094,255

 

 

994,339

 

 

 

 

NONCURRENT ASSETS:

 

 

 

Property and equipment, net

 

120,630

 

 

108,321

Intangible assets, net

 

20,092

 

 

22,371

Referral sources, net

 

315,304

 

 

341,744

Goodwill

 

1,540,246

 

 

1,533,424

Other noncurrent assets

 

126,508

 

 

112,737

Total noncurrent assets

 

2,122,780

 

 

2,118,597

TOTAL ASSETS

$

3,217,035

 

$

3,112,936

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

CURRENT LIABILITIES:

 

 

 

Accounts payable

$

426,513

 

$

378,763

Other current liabilities

 

191,796

 

 

186,588

Total current liabilities

 

618,309

 

 

565,351

 

 

 

 

NONCURRENT LIABILITIES:

 

 

 

Long-term debt, net of discount, deferred financing costs and current portion

 

1,056,650

 

 

1,058,204

Other noncurrent liabilities

 

120,404

 

 

103,278

Total noncurrent liabilities

 

1,177,054

 

 

1,161,482

Total liabilities

 

1,795,363

 

 

1,726,833

 

 

 

 

STOCKHOLDERS' EQUITY

 

1,421,672

 

 

1,386,103

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

3,217,035

 

$

3,112,936

 


Schedule 2

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)

 


 

Three Months Ended
December 31,

 

Year Ended
December 31,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

NET REVENUE

$

1,124,390

 

 

$

1,027,213

 

 

$

4,302,324

 

 

$

3,944,735

 

COST OF REVENUE

 

877,267

 

 

 

796,132

 

 

 

3,321,101

 

 

 

3,077,817

 

GROSS PROFIT

 

247,123

 

 

 

231,081

 

 

 

981,223

 

 

 

866,918

 

 

 

 

 

 

 

 

 

OPERATING COSTS AND EXPENSES:

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

147,783

 

 

 

148,351

 

 

 

607,427

 

 

 

566,122

 

Depreciation and amortization expense

 

14,784

 

 

 

14,538

 

 

 

59,201

 

 

 

60,565

 

Total operating expenses

 

162,567

 

 

 

162,889

 

 

 

666,628

 

 

 

626,687

 

OPERATING INCOME

 

84,556

 

 

 

68,192

 

 

 

314,595

 

 

 

240,231

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE):

 

 

 

 

 

 

 

Interest expense, net

 

(12,432

)

 

 

(14,798

)

 

 

(51,248

)

 

 

(53,806

)

Other, net

 

6,801

 

 

 

11,387

 

 

 

95,395

 

 

 

19,343

 

Total other (expense) income

 

(5,631

)

 

 

(3,411

)

 

 

44,147

 

 

 

(34,463

)

 

 

 

 

 

 

 

 

INCOME BEFORE INCOME TAXES

 

78,925

 

 

 

64,781

 

 

 

358,742

 

 

 

205,768

 

INCOME TAX EXPENSE

 

21,748

 

 

 

17,252

 

 

 

91,652

 

 

 

55,212

 

NET INCOME

$

57,177

 

 

$

47,529

 

 

$

267,090

 

 

$

150,556

 

 

 

 

 

 

 

 

 

Earnings per share, basic

$

0.32

 

 

$

0.26

 

 

$

1.49

 

 

$

0.83

 

Earnings per share, diluted

$

0.32

 

 

$

0.26

 

 

$

1.48

 

 

$

0.83

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic

 

176,055

 

 

 

181,925

 

 

 

178,973

 

 

 

181,105

 

Weighted average common shares outstanding, diluted

 

177,743

 

 

 

183,086

 

 

 

180,375

 

 

 

182,075

 

  


Schedule 3

OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)

 


 

Year Ended
December 31,

 

 

2023

 

 

 

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

Net income

$

267,090

 

 

$

150,556

 

Adjustments to reconcile net income to net cash provided by operations:

 

 

 

Depreciation and amortization expense

 

62,200

 

 

 

65,434

 

Deferred income taxes - net

 

12,766

 

 

 

49,187

 

Other non-cash adjustments

 

50,684

 

 

 

32,147

 

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

224

 

 

 

(36,889

)

Inventories

 

(51,000

)

 

 

(41,010

)

Accounts payable

 

47,703

 

 

 

98,885

 

Other

 

(18,372

)

 

 

(50,763

)

Net cash provided by operating activities

 

371,295

 

 

 

267,547

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

Acquisition of property and equipment

 

(41,866

)

 

 

(35,358

)

Proceeds from sale of assets

 

3,743

 

 

 

14,670

 

Business acquisitions, net of cash acquired

 

(12,494

)

 

 

(87,364

)

Other investing activities

 

(5,889

)

 

 

 

Net cash used in investing activities

 

(56,506

)

 

 

(108,052

)

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

Proceeds from warrant exercises

 

 

 

 

20,916

 

Purchase of company stock

 

(250,261

)

 

 

 

Other financing activities

 

(14,865

)

 

 

(5,648

)

Net cash (used in) provided by financing activities

 

(265,126

)

 

 

15,268

 

 

 

 

 

NET INCREASE IN CASH AND CASH EQUIVALENTS

 

49,663

 

 

 

174,763

 

Cash and cash equivalents - beginning of the period

 

294,186

 

 

 

119,423

 

CASH AND CASH EQUIVALENTS - END OF PERIOD

$

343,849

 

 

$

294,186

 

 


Schedule 4

OPTION CARE HEALTH, INC.
RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS)(UNAUDITED)

 


 

Three Months Ended 
 December 31,

 

Year Ended
December 31,

 

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Net income

$

57,177

 

 

$

47,529

 

 

$

267,090

 

 

$

150,556

 

Interest expense, net

 

12,432

 

 

 

14,798

 

 

 

51,248

 

 

 

53,806

 

Income tax expense

 

21,748

 

 

 

17,252

 

 

 

91,652

 

 

 

55,212

 

Depreciation and amortization expense

 

15,777

 

 

 

15,711

 

 

 

62,200

 

 

 

65,434

 

EBITDA

 

107,134

 

 

 

95,290

 

 

 

472,190

 

 

 

325,008

 

 

 

 

 

 

 

 

 

EBITDA adjustments

 

 

 

 

 

 

 

Stock-based incentive compensation expense

 

7,571

 

 

 

4,202

 

 

 

30,479

 

 

 

16,783

 

Gain on sale of assets

 

 

 

 

(10,325

)

 

 

 

 

 

(10,325

)

Restructuring, acquisition, integration and other (1)

 

(3,103

)

 

 

5,105

 

 

 

(77,486

)

 

 

11,387

 

Adjusted EBITDA

$

111,602

 

 

$

94,272

 

 

$

425,183

 

 

$

342,853

 

 

(1) Restructuring, acquisition, integration and other for the year ended December 31, 2023 includes the Amedisys merger termination fee, net of merger-related expenses


Advertisement